SLC5A2 and kidney disorder: Positive results of DAPA-CKD [48] and EMPA-Kidney [50], the two large scale randomised controlled trials of SGLT2 inhibitors in subjects with pre-existing impaired renal function as the primary inclusion criterion, encourage the use of SGLT2 inhibitors in individuals with kidney disease regardless of coexisting T2DM.